Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080145 · ClinicalTrials.gov registry record · NA
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
A NA study of Child Development Disorders, Pervasive, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
- 3
- Study locations
NCT00080145: Completed NA study of Child Development Disorders, Pervasive, sponsored by Yale University.
NCT00080145 is a NA study of Child Development Disorders, Pervasive that has completed, run by Yale University. The registered enrollment target is 124 participants, above the 78-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (59% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080145, a NA study of Child Development Disorders, Pervasive, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
- 3
- Study locations
Study Summary
This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.
Conditions Studied
Interventions
- DRUG Risperidone
- BEHAVIORAL Behavior Therapy
Study Locations (3)
Connecticut
- Yale University - New Haven
Indiana
- Indiana University - Indianapolis
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-09 |
| Phase | NA |
What the finished NCT00080145 record still lists
NCT00080145 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 78-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (59% higher).
The record links to 1 condition, with Child Development Disorders, Pervasive appearing as the primary indexed condition, and to 2 interventions - of which Risperidone is the first listed.
NCT00080145 reports a single indexed study location in Connecticut, Indiana, Ohio.
Frequently Asked Questions
What is clinical trial NCT00080145 about?
NCT00080145 is a clinical study titled "RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders". This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.
What is the current status of trial NCT00080145?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2004-02. Estimated completion is 2007-09.
What conditions does trial NCT00080145 study?
This clinical trial studies the following conditions: Child Development Disorders, Pervasive.
What interventions are being tested in trial NCT00080145?
The interventions under investigation include: Risperidone (DRUG), Behavior Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00080145?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00080145 being conducted?
This trial has 3 study locations across Connecticut, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Child Development Disorders, Pervasive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
COMPLETED · Phase 1
-
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
COMPLETED · Phase 1
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia